Eden vs. SkinnyRx: prices, fine print, and the honest verdict

Tirzepatide pricing

On tirzepatide, SkinnyRx is the cheaper program at $299 a month all-in versus Eden's $408 — a gap of $109 a month, $1,308 a year, at the 10 mg maintenance basis. Eden: $408 a month all-in at the 10 mg maintenance basis, dose-scaled from a $348 entry, including the mandatory $99/mo membership. SkinnyRx: $299 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee.

Semaglutide pricing

On semaglutide, Eden wins at $198 versus $199 all-in — $1/mo apart. Eden: Semaglutide runs $198 a month all-in. SkinnyRx: Semaglutide runs $199 a month all-in.

Transparency

Eden: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. SkinnyRx: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Eden: membership auto-renews; membership auto-renews until cancelled; $99/mo membership recurs until cancelled. SkinnyRx: none; no membership on compounded programs.

The gap, compounded over time

Price gaps in this market are best read on a calendar. Eden's premium over SkinnyRx compounds to: one month, $109; six months, $654; a year, $1,308; two years of maintenance, $2,616. Every figure is the all-in maintenance basis; the arithmetic reruns from the dataset.

The 24-month ledger

The two-year totals put the monthly gap in its true scale: Eden bills $9,792 and SkinnyRx $7,176, a spread of $2,616 for the same molecule at the same 10 mg basis. Reference rails for the same 24 months: $5,160 at the verified floor, $10,776 on brand Zepbound at maintenance, $8,376 on Wegovy flat.

Two ladders, side by side

Titration is where these pricing structures stop being abstractions: Eden scales $348 → ~$408 by 10 mg (titration lands between $1,392 and $1,632); SkinnyRx holds $299 on every rung (four-month titration: exactly $1,196). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

Three buyers, two invoices

The month-one starter pays $348 at Eden versus $299 at SkinnyRx for the 2.5 mg rung — an early edge that holds once the ladder climbs. The settled 10 mg maintainer — the buyer our basis is built for — pays $3,588/year at SkinnyRx against $4,896 at the other: $1,308 of annual daylight for the same molecule and dose.

The semaglutide board

The boards split: on semaglutide the order flips, with Eden cheaper at $198 against $199 — a reminder that molecule choice can decide the provider question by itself. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. Eden's ranked figure is $408 ($309 medication + $99 mandatory membership); SkinnyRx's ranked figure is $299, with no membership to add. 2 · Maintenance basis. Eden scales from $348 to $408, and the 10 mg figure is the one ranked; SkinnyRx is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. Eden: standing $408, no prepaid tier; SkinnyRx: standing $299, no prepaid tier — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Eden: source-verified, read 2026-08-05; SkinnyRx: source-verified, read 2026-08-05. 5 · Pharmacy weighed. Eden names no pharmacy; SkinnyRx names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Eden: a mandatory $99/mo membership folded into our all-in figure; membership auto-renews until cancelled. SkinnyRx: no membership — the medication figure is the billed figure; no membership on compounded programs; commitment: none. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Eden carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. SkinnyRx carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

The switch mechanics are symmetric: new intake, new script, new pharmacy, old plan cancelled in writing. Budget a shipping-gap week, confirm the destination program's price at your current dose (not its starter figure), and if the move is also a molecule change, loop the prescriber in per the switching guide.

Refills, shipping, and the week-to-week reality

Logistics decide more churn than price does, so put them on the record: Eden: shipping included; consultation included in membership; async visit model. SkinnyRx: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Eden if the semaglutide line is cheaper here. Pick SkinnyRx if the $109/month tirzepatide saving is the point; you want a price that survives titration; you refuse membership fees on principle. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

Widen the frame one step and the strongest adjacent options are Lavender Sky Health at $352 (dose-scaled, $25 membership included); Henry Meds at $349 (flat, no membership); TrimRx at $349 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $1,800/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

On the numbers alone, SkinnyRx is the cheaper tirzepatide program by $109/mo and it doesn't trade that price for opacity ; Eden's case rests on a cheaper semaglutide line. Both records, with dates and sources, live in the pricing database.